

# Prof. Faith Hope Among'in Osier

## Publications (h-index 36) & Book Chapters

---

1. Dennis Odera, James Tuju, Kennedy Mwai, Irene N Nkumama, Kristin Furle, Timothy Chege, Rinter Kimathi, Fauzia K Musasia, ..... and **Faith HA Osier** Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria. *Sci Transl Med* 2023 Feb 8;15(682):eabn5993.
2. Lindsey Baden, Flaminia Catterucia, Abdoulaye Diabete, Cristina Donini, Francois Nosten, Scott O'Neill, **Faith Osier**, Aung Pyae Phyo and Niholas White. *Malaria-Epidemiology, Treatment, and Prevention. N Engl J Med* 2023 Feb 2;388(5):e9.
3. Micha Rosenkranz, Irene N Nkumama, Sara Kraker, Marie Blickling, Kennedy Mwai, Dennis Odera, James Tuju, Kristin Fürle, Roland Frank, Emily Chepsat, Melissa C Kapulu, **Faith HA Osier**, CHMI-SIKA study team. Full-length merozoite surface protein 1 of *Plasmodium falciparum* is a major target of protective immunity following controlled human malaria infections. *medRxiv* 2022/1/1
4. Irene Nailain Nkumama, Dennis Odera, Fauzia Musasia, Kennedy Mwai, Lydia Nyamako, Linda Murungi, James Tuju, Kristin Furle, Micha Rosenkranz, Rinter Kimathi, Patricia Njuguna, Mainga Hamaluba, Melissa C Kapulu, Roland Frank, **Faith Osier**, CHMI-SIKA Study Team. Breadth of Fc-mediated effector function delineates grades of clinical immunity following human malaria challenge. *bioRxiv* 2022/1/1
5. Tim Starck, Peter Dambach, Toussaint Rouamba, Halidou Tinto, **Faith Osier**, Catherine E Oldenburg, Maya Adam, Till Bärnighausen, Thomas Jaenisch, Caroline A Bulstra. The effect of malaria on childhood anemia in a quasi-experimental study of 7,384 twins from 23 Sub-Saharan African countries. *Front Public Health* 2022, Dec 6;10:1009865. doi: 10.3389/fpubh.2022.1009865
6. Natalia Fernandez, Peter Hayes, Julia Makinde, Jonathan Hare, Deborah King, Rui Xu, Ola Rehawi, Allison T Mezzell, Lana Kato, Susan Mugaba, Jennifer Serwanga, James Chemweno, Eunice Nduati, Matt A Price, **Faith Osier**, Christina Ochsenbauer, Ling Yue, Eric Hunter, Jill Gilmour, IAVI protocol C investigators. Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay. *Front Immunol* 2022, Dec 1;13:1029029.doi: 10.3389/fimmu.2022.1029029.
7. Marco Vincenzo Lenti, Sarah Luu, Rita Carsetti, **Faith Osier**, Rodny Ogwang, Obiageli E Nnodu, Ursula Wiedermann, Jo Spencer, Franco Locatelli, Gino Roberto Corazza, Antonio Di Sabatino. Asplenia and spleen hypofunction. *Nat Rev Dis Primers* 2022, Nov Nov 3;8(1):71.doi: 10.1038/s41572-022-00399-x
8. Kennedy Mwai, Irene Nkumama, Amos Thairu, James Mburu, Dennis Odera, Rinter Kimathi, Lydia Nyamako, James Tuju, Samson Kinyanjui, Eustasius Musenge, **Faith Osier** Estimating Malaria Attributable Fractions With Changing Transmission Intensity: Bayesian Latent Class Vs Logistic Models, *Malar J* 2022, Nov 2022 Nov 11;21(1):326 doi10.1186/s12936-022-04346-9
9. Musasia FK, Nkumama IN, Frank R, Kipkemboi V, Schneider M, Mwai K, Odera DO, Rosenkranz M, Fürle K, Kimani D, Tuju J, Njuguna P, Hamaluba M, Kapulu MC, Wardemann H; CHMI-SIKA Study Team, and **Osier FHA**. Phagocytosis of *Plasmodium Falciparum* ring-

stage parasites predicts protection against malaria Nat Commun. 2022 Jul 14;13(1):4098. doi: 10.1038/s41467-022-31640-6 PMID: 35835738

10. Brenda Oseno, Faith Marura, Rodney Ogwang, Martha Muturi, James Njunge, Irene Nkumama, Robert Mwakesi, Kennedy Mwai, Martin K Rono, Ramadhan Mwakubambanya, **Faith Osier**, James Tuju. Characterization of Anopheles gambiae D7 salivary proteins as markers of human-mosquito bite contact. Parasit Vectors 2022 Jan 8;15(1):11, doi: 10.1186/s13071-021-05130-5 PMID 34996508
11. Melissa C Kapulu, Domtila Kimani, Patricia Njuguna, Mainga Hamaluba, Edward Otieno, Rinter Kimathi, James Tuju, B Kim Lee Sim, CHMI SIKA Study Team (incl. **Osier FHA**). Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response. BMC Infect Dis 2022 Jan 24;22(1):86 doi: 10.1186/s12879-022-07044-8 PMID 35073864
12. Victor Yman, James Tuju, Michael T White, Gathoni Kamuyu, Kennedy Mwai, Nelson Kibinge, Muhammad Asghar, Christopher Sundling, Klara Sondén, Linda Murungi, Daniel Kiboi, Rinter Kimathi, Timothy Chege, Emily Chepsat, Patience Kiyuka, Lydia Nyamako, **Faith H A Osier**, Anna Färnert. Distinct kinetics of antibodies to 111 Plasmodium falciparum proteins identifies markers of recent malaria exposure Nat Commun 2022 Jan 17;13(1):331 doi: 10.1038/s41467-021-27863-8. PMID: 35039519
13. Duncan Ndungu Ndegwa, James Tuju, Emily Chepsat, Rinter Kimathi, Kennedy Mwai, Lydia Nyamako, Baba Dieye, Moses Mosobo, Awa Bineta Deme, Ibrahima Mbaye Ndiaye, Mouhamad Sy, Younous Diedhiou, Amadou Moctar Mbaye, Dyann Wirth, Daouda Ndiaye, **Faith Osier**, Amy Kristine High-throughput profiling of natural acquired humoral immune response to a large panel of known and novel full length ectodomain *P. falciparum* merozoite vaccine candidates under reduced malaria transmission Preprint bioRxiv.org Publication date 01/01/2022
14. Irene N Nkumama, **Faith H A Osier** Malaria vaccine roller coaster Nat Microbiol 2021 Oct 11; Online ahead of print, doi: 10.1038/s41564-021-00982-0; PMID 34635830
15. Melissa C Kapulu, Patricia Njuguna, Mainga Hamaluba, Domtila Kimani, Joyce M Ngoi, Janet Musembi, Omar Ngoto, Edward Otieno, Peter F Billingsley, Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA Study Team (incl. **Osier FHA**). Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection. JCI Insight 2021 Sep 8;6(17):e146443
16. Primus Che Chi, Esther Awuor Owino, Irene Jao, Fredrick Olewe, Bernhards Ogutu, Philip Bejon, Melissa Kapulu, Dorcas Kamuya, Vicki Marsh, CHMI-SIKA Study Team (incl. **Osier FHA**). Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders. Trials 2021 Jul 26;22(1):494. doi: 10.1186/s13063-021-05455-7.
17. Botwe, AK, Oppong, FB, Gyaase, S, Owusu-Agyei S, Asghar M, Asante KP, Färnert A and **Osier F**. Determinants of the varied profiles of Plasmodium falciparum infections among infants living in Kintampo, Ghana. Malar J. 2021 May 29; 20, 240. doi: 10.1186/s12936-021-03752-9
18. Lane R. **Faith Osier**: inspirational immunologist. Lancet. 2021 Apr 24;397(10284):1533. doi: 10.1016/S0140-6736(21)00839-4.
19. Mwai K, Kibinge N, Tuju J, Kamuyu G, Kimathi R, Mburu J, Chepsat E, Nyamako L, Chege T, Nkumama I, Kinyanjui S, Musenge E, and **Osier F**. protGear: A protein microarray data pre-processing suite. Comput Struct Biotechnol J 2021 Apr 24; 19:2518-2525. doi: 10.1016/j.csbj.2021.04.044

20. **Osier FHA**, Murungi LM. Smashing Stereotypes: Mutual Respect, Key to Embracing Diversity. *Trends Parasitol.* 2021 Jan 29;S1471-4922(21)00007-6. doi: 10.1016/j.pt.2021.01.004.
21. Niare K, Chege T, Mwai K, Tuju J, Nyamako L, Rosenkranz M, Tiono A, Waitumbi J, Ogutu B, Sirima S, Awandare G, Kouriba B, Rayner J, **Osier F**. Systemic Serological Diversity of a Putative Malaria Vaccine Candidate and Broad Protection. Preprint, Research Square, Dec 2020, doi: 10.21203/rs.3.rs-109750/v1
22. Botwe AK, Owusu-Agyei S, Asghar M, Hammar U, Oppong FB, Gyaase S, Dosoo D, Jakpa G, Boamah E, Twumasi MF, **Osier F**, Färnert A, Asante KP. Profiles of *Plasmodium falciparum* infections detected by microscopy through the first year of life in Kintampo a high transmission area of Ghana. *PLoS One.* 2020 Oct 19;15(10):e0240814. doi: 10.1371/journal.pone.0240814. eCollection 2020.
23. **Osier F**, Ting JPY, Fraser J, Lambrecht BN, Romano M, Gazzinelli RT, Bortoluci KR, Zamboni DS, Akbar AN, Evans J, Brown DE, Patel KD, Wu Y, Perez AB, Pérez O, Kamradt T, Falk C, Barda-Saad M, Ariel A, Santoni A, Annunziato F, Cassatella MA, Kiyono H, Chereshev V, Dieye A, Mbow M, Mbengue B, Niang MDS, Suchard M. The global response to the Covid-19 pandemic: how have immunology societies contributed *Nat Rev Immunol.* 2020 Oct;20(10):594-602.
24. **Osier F**, Uzonna JE. Editorial: Regulation of Immunity to Parasitic Infections Endemic to Africa *Front Immunol.* 2020 Jun 12;11:1159. doi: 10.3389/fimmu.2020.01159.
25. **Osier FHA**, Mwandumba HC, Gray CM. Turning Discoveries into Treatments: Immunology in Africa *Trends Immunol.* 2020 Dec;41(12):1051-1053.
26. Aniweh Y, Nyarko PB, Charles-Chess E, Ansah F, **Osier FHA**, Quansah E, Thiam LG, Kamuyu G, Marsh K, Conway DJ, Tetteh KKA, Awandare GA. *Plasmodium falciparum* Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria. *Front Immunol.* 2020 Apr 7;11:505. doi: 10.3389/fimmu.2020.00505.
27. Niespodziana K, Borochova K, Pazderova P, Schleder T, Astafyeva N, Baranovskaya T, Barbouche MR, Beltyukov E, Berger A, Borzova E, Bousquet J, Bumbacea RS, Bychkovskaya S, Caraballo L, Chung KF, Custovic A, Docena G, Eiwegger T, Evsegneeva I, Emelyanov A, Errhalt P, Fassakhov R, Fayzullina R, Fedenko E, Fomina D, Gao Z, Giavina-Bianchi P, Gotua M, Greber-Platzer S, Hedlin G, Ilina N, Ispayeva Z, Idzko M, Johnston SL, Kalayci Ö, Karaulov A, Karsonova A, Khaitov M, Kovzel E, Kowalski ML, Kudlay D, Levin M, Makarova S, Matricardi PM, Nadeau KC, Namazova-Baranova L, Naumova O, Nazarenko O, O'Byrne PM, **Osier F**, Pampura AN, Panaitescu C, Papadopoulos NG, Park HS, Pawankar R, Pohl W, Renz H, Riabova K, Sampath V, Sekerel BE, Sibanda E, Siroux V, Sizyakina LP, Sun JL, Szepefalusi Z, Umanets T, Van Bever HPS, van Hage M, Vasileva M, von Mutius E, Wang JY, Wong GWK, Zaikov S, Zidarn M, Valenta R. Toward personalization of asthma treatment according to trigger factors. *J Allergy Clin Immunol.* 2020 Feb 18:S0091-6749(20)30193-7.
28. Melissa C Kapulu, Patricia Njuguna, Mainga M Hamaluba, CHMI-SIKA Study Team (incl. **Osier FHA**) Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo *Plasmodium falciparum* malaria parasite growth in the context of pre-existing immunity *Wellcome Open Res* 2019 Nov 14;3:155. doi:10.12688/wellcomeopenres.14909.2. eCollection 2018.

29. Njuguna P, Maitland K, Nyaguara A, Mwanga D, Mogeni P, Mturi N, Mohammed S, Mwambingu G, Ngetsa C, Awuondo K, Lowe B, Adetifa I, Scott JAG, Williams TN, Atkinson S, **Osier F**, Snow RW, Marsh K, Tsofa B, Peshu N, Hamaluba M, Berkley JA, Newton CRJ, Fondo J, Omar A, Bejon P. Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya. *BMC Med.* 2019 Jul 8;17(1):124.
30. Murungi LM, Kimathi RK, Tuju J, Kamuyu G, **Osier FHA**. Serological Profiling for Malaria Surveillance Using a Standard ELISA Protocol. *Methods Mol Biol.* 2019; 2013:83-90.
31. Wamae K, Wambua J, Nyangweso G, Mwambingu G, **Osier F**, Ndung'u F, Bejon P, Ochola-Oyier LI. Transmission and Age Impact the Risk of Developing Febrile Malaria in Children with Asymptomatic *Plasmodium falciparum* Parasitemia. *J Infect Dis.* 2019 Feb 23;219(6):936-944. doi: 10.1093/infdis/jiy591.
32. Yman V, White MT, Asghar M, Sundling C, Sondén K, Draper SJ, **Osier FHA**, Färnert A. Antibody responses to merozoite antigens after natural *Plasmodium falciparum* infection: kinetics and longevity in absence of re-exposure. *BMC Med.* 2019 Jan 30;17(1):22.
33. Kamuyu G, Tuju J, Kimathi R, Mwai K, Mburu J, Kibinge N, Chong Kwan M, Hawkings S, Yaa R, Chepsat E, Njunge JM, Chege T, Guleid F, Rosenkranz M, Kariuki CK, Frank R, Kinyanjui SM, Murungi LM, Bejon P, Färnert A, Tetteh KKA, Beeson JG, Conway DJ, Marsh K, Rayner JC, **Osier FHA**. KILchip v1.0: A Novel *Plasmodium falciparum* Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. *Front Immunol.* 2018 Dec 11;9:2866.
34. Feng G, Boyle MJ, Cross N, Chan JA, Reiling L, **Osier F**, Stanisic DI, Muellerl, Anders RF, McCarthy JS, Richards JS, Beeson JG. Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains. *J Infect Dis.* 2018 Jun 5;218(1):35-43.
35. Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbé GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, **Osier FH**, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. *JCI Insight.* 2017 Nov 2;2(21).
36. Mugenyi CK, Elliott SR, Yap XZ, Feng G, Boeuf P, Fegan G, **Osier FH**, Fowkes FJI, Avril M, Williams TN, Marsh K, Beeson JG. Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to *Plasmodium falciparum* in Children. *J Infect Dis.* 2017 Oct 17;216(7):887-898.
37. Abdi AI, Hodgson SH, Muthui MK, Kivisi CA, Kamuyu G, Kimani D, Hoffman SL, Juma E, Ogutu B, Draper SJ, **Osier F**, Bejon P, Marsh K, Bull PC. *Plasmodium falciparum* malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure. *BMC Infect Dis.* 2017 Aug 23;17(1):585.
38. Bryan D, Silva N, Rigsby P, Dougall T, Corran P, Bowyer PW, Ho MM; Collaborative study group. The establishment of a WHO Reference Reagent for anti-malaria (*Plasmodium falciparum*) human serum. *Malar J.* 2017 Aug 5;16(1):314.
39. Offeddu V, Olotu A, **Osier F**, Marsh K, Matuschewski K, Thaty V. High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria. *Front Immunol.* 2017 May 8;8:488.

40. Tuju J, Kamuyu G, Murungi LM, **Osier FHA**. Vaccine candidate discovery for the next generation of malaria vaccines. *Immunology*. 2017 Oct;152(2):195-206
41. Nkumama IN, O'Meara WP, **Osier FH**. Changes in Malaria Epidemiology in Africa and New Challenges for Elimination. *Trends Parasitol*. 2017 Feb;33(2):128-140.
42. Murungi LM, Sondén K, Odera D, Oduor LB, Guleid F, Nkumama IN, Otiende M, Kangoye DT, Fegan G, Färnert A, Marsh K, **Osier FH**. Cord blood IgG and the risk of severe *Plasmodium falciparum* malaria in the first year of life. *Int J Parasitol*. 2017 Feb;47(2-3):153-162.
43. Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, Kamuyu G, Juma EA, Magiri C, Muia A, Jin J, Spencer AJ, Longley RJ, Mercier T, Decosterd L, Long CA, **Osier FH**, Hoffman SL, Ogutu B, Hill AV, Marsh K, Draper SJ. Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. *Front Microbiol*. 2016 Oct 13;7:1604. doi: 10.3389/fmicb.2016.01604. PMID: 27790201; PMCID: PMC5061779.
44. Boyle MJ, Reiling L, **Osier FH**, Fowkes FJ. Recent insights into humoral immunity targeting *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Int J Parasitol*. 2016 Jul 20. pii: S0020-7519(16)30137-0.
45. Mogeni P, Williams TN, Fegan G, Nyundo C, Bauni E, Mwai K, Omedo I, Njuguna P, Newton CR, **Osier F**, Berkley JA, Hammitt LL, Lowe B, Mwambingu G, Awuondo K, Mturi N, Peshu N, Snow RW, Noor A, Marsh K, Bejon P. Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study. *PLoS Med*. 2016 Jun 28;13(6):e1002047.
46. Yman V, White MT, Rono J, Arcà B, **Osier FH**, Troye-Blomberg M, Boström S, Ronca R, Rooth I, Färnert A. Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity. *Sci Rep*. 2016 Feb 5;6:19472. doi:10.1038/srep19472.
47. Murungi LM, Sondén K, Llewellyn D, Rono J, Guleid F, Williams AR, Ogada E, Thairu A, Färnert A, Marsh K, Draper SJ, **Osier FH**. Severe *Plasmodium falciparum* malaria: targets and mechanisms associated with protection in Kenyan children. *Infect Immun*. 2016 Jan 19. pii: IA1.01120-15. [Epub ahead of print]
48. Kangoye DT, Mensah VA, Murungi LM, Nkumama I, Nebie I, Marsh K, Cisse B, Bejon P, **Osier FH**, Sirima SB; MVVC Infant Immunology Study Group. Dynamics and role of antibodies to *Plasmodium falciparum* merozoite antigens in children living in two settings with differing malaria transmission intensity. *Vaccine*. 2016 Jan 2;34(1):160-6. doi: 10.1016/j.vaccine.2015.10.058. Epub 2015 Nov 11.
49. Llewellyn D, Miura K, Fay MP, Williams AR, Murungi LM, Shi J, Hodgson SH, Douglas AD, **Osier FH**, Fairhurst RM, Diakite M, Pleass RJ, Long CA, Draper SJ. Standardization of the antibody-dependent respiratory burst assay with human neutrophils and *Plasmodium falciparum* malaria. *Sci Rep*. 2015 Sep 16;5:14081.
50. Tanner M, Greenwood B, Whitty CJ, Ansah EK, Price RN, Dondorp AM, von Seidlein L, Baird JK, Beeson JG, Fowkes FJ, Hemingway J, Marsh K, **Osier F**. Malaria eradication and elimination: views on how to translate a vision into reality. *BMC Med*. 2015 Jul 25;13:167.
51. Rono J, Färnert A, Murungi L, Ojal J, Kamuyu G, Guleid F, Nyangweso G, Wambua J, Kitsao B, Olotu A, Marsh K, **Osier FH**. Multiple clinical episodes of *Plasmodium falciparum* malaria in a low transmission intensity setting: exposure versus immunity. *BMC Med*. 2015 May 13;13(1):114.

52. Hodgson SH, Juma E, Salim A, Magiri C, Njenga D, Molyneux S, Njuguna P, Awuondo K, Lowe B, Billingsley PF, Cole AO, Ogwang C, **Osier F**, Chilengi R, Hoffman SL, Draper SJ, Ogutu B, Marsh K. Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. *Malar J*. 2015 Apr 28;14(1):182.
53. Boyle MJ, Reiling L, Feng G, Langer C, **Osier FH**, Aspelting-Jones H, Cheng YS, Stubbs J, Tetteh KK, Conway DJ, McCarthy JS, Muller I, Marsh K, Anders RF, Beeson JG. Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria. *Immunity*. 2015 Mar 17;42(3):580-90.
54. Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, Muia A, Cole AO, Ogwang C, Awuondo K, Lowe B, Munene M, Billingsley PF, James ER, Gunasekera A, Sim BK, Njuguna P, Rampling TW, Richman A, Abebe Y, Kamuyu G, Muthui M, Elias SC, Molyneux S, Gerry S, Macharia A, Williams TN, Bull PC, Hill AV, **Osier FH**, Draper SJ, Bejon P, Hoffman SL, Ogutu B, Marsh K. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. *Front Microbiol*. 2014 Dec 12;5:686.
55. Terheggen U, Drew DR, Hodder AN, Cross NJ, Mugenyi CK, Barry AE, Anders RF, Dutta S, **Osier F**, Elliott SR, Senn N, Stanisic DI, Marsh K, Siba PM, Mueller I, Richards JS, Beeson JG. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines. *BMC Med*. 2014 Oct 16;12(1):183.
56. Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, **Osier FH**, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ. Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. *PLoS One*. 2014 Sep 25;9(9):e107903. doi:10.1371/journal.pone.0107903.
57. Hodgson, S, Juma, E, Salim, A et al. Controlled human malaria infection in Kenyan adults: A safe model that could accelerate assessment of novel drugs and vaccines in malaria endemic populations. *Malar J*. 2014 Sep 22; 13, O33. doi: 10.1186/1475-2875-13-S1-O33
58. **Osier FH**, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M, Ogada E, McDade B, Rayner JC, Wright GJ, Marsh K. New antigens for a multicomponent blood-stage malaria vaccine. *Sci Transl Med*. 2014 Jul 30;6(247):247ra102.
59. **Osier FHA**, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders R, Marsh K, Beeson JG. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. *BMC Med*. 2014 Jul 1;12:108..
60. Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, Nutman TB, Ngugi AK, Odhiambo R, Wagner RG, Kakooza-Mwesige A, Owusu-Agyei S, Ae-Ngibise K, Masanja H, **Osier FH**, Odermatt P, Newton CR; Study of Epidemiology of Epilepsy in Demographic Sites (SEEDS) group. Exposure to multiple parasites is associated with the prevalence of active convulsive epilepsy in sub-saharan Africa. *PLoS Negl Trop Dis*. 2014 May 29;8(5):e2908.
61. Crosnier C, Wanaguru M, McDade B, **Osier FH**, Marsh K, Rayner JC, Wright GJ. A library of functional recombinant cell-surface and secreted *P. falciparum* merozoite proteins. *Mol Cell Proteomics*. 2013 Dec;12(12):3976-86.
62. Rono J, **Osier FH**, Olsson D, Montgomery S, Mhoja L, Rooth I, Marsh K, Färnert A. Breadth of Anti-Merozoite Antibody Responses is Associated with the Genetic Diversity of Asymptomatic *Plasmodium falciparum* Infections and Protection against Clinical Malaria. *Clin*

63. Tetteh KK, **Osier FH**, Salanti A, Kamuyu G, Drought L, Faily M, Martin C, Marsh K, Conway DJ. Analysis of antibodies to newly described *Plasmodium falciparum* merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity. *Infect Immun*. 2013 Oct;81(10):3835-42.
64. Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui SM, Marsh K, **Osier FH**. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. *Vaccine*. 2013, 31(37):3936-42.
65. Warimwe GM, Murungi LM, Kamuyu G, Nyangweso GM, Wambua J, Naranbhai V, Fletcher HA, Hill AV, Bejon P, **Osier FH**, Marsh K. The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children. *PLoS One*. 2013;8(2):e57320. doi:10.1371/journal.pone.0057320.
66. Lundblom K, Murungi L, Nyaga V, Olsson D, Rono J, **Osier F**, Ogada E, Montgomery S, Scott JA, Marsh K, Färnert A. *Plasmodium falciparum* infection patterns since birth and risk of severe malaria: a nested case-control study in children on the coast of Kenya. *PLoS One*. 2013;8(2):e56032. doi:10.1371/journal.pone.0056032.
67. Rono J, Färnert A, Olsson D, **Osier F**, Rooth I, Persson KE. *Plasmodium falciparum* line-dependent association of in vitro growth-inhibitory activity and risk of malaria. *Infect Immun*. 2012, 80(5):1900-8.
68. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ, Long CA, **Osier FH**, Marsh K, Turner AV, Hill AV, Draper SJ. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. *Nat Commun*. 2011, 2:601. doi: 10.1038/ncomms1615.
69. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, Frühauf H, Schaub B, Pfeil J, Peshu J, Hanpithakpong W, Rippert A, Juma E, Tsofa B, Mosobo M, Lowe B, **Osier F**, Fegan G, Lindegårdh N, Nzila A, Peshu N, Mackinnon M, Marsh K. Declining responsiveness of *Plasmodium falciparum* infections to artemisinin-based combination treatments on the Kenyan coast. *PLoS One*. 2011;6(11):e26005.doi:10.1371/journal.pone.0026005.
70. **Osier FHA**, Weedall GD, Verra F, Murungi L, Tetteh KKA, Bull P, Faber BW, Remarque E, Thomas A, Marsh K, Conway DJ. Allelic diversity and naturally acquired allele-specific antibody responses to *Plasmodium falciparum* apical membrane antigen 1 in Kenya. *Infect Immun*. 2010 Nov;78(11):4625-33.
71. Bejon P, Williams TN, Liljander A, Noor AM, Wambua J, Ogada E, Olotu A, **Osier FH**, Hay SI, Färnert A, Marsh K. Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. *PLoS Med*. 2010 Jul 6;7(7):e1000304.
72. **Osier FHA**, Murungi LM, Fegan G, Tuju J, Tetteh KK, Bull PC, Conway DJ, Marsh K. <sup>[1]</sup><sub>SEP</sub> Allele-specific antibodies to *Plasmodium falciparum* merozoite surface protein-2 and protection against clinical malaria. *Parasite Immunol*. 2010, 32, 193-201
73. Kinyanjui SM, Bejon P, **Osier FHA**, Bull PC, Marsh K<sup>[1]</sup><sub>SEP</sub> What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. *Malar. J*. 2009 Oct 28;8:242
74. Berkley JA, Bejon P, Mwangi T, Gwer S, Maitland K, Williams TN, Mohammed S, **Osier F**, Kinyanjui S, Fegan G, Lowe BS, English M, Peshu N, Marsh K, Newton CR. HIV infection,

- malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis. 2009 Aug 1;49(3):336-43.
75. Bejon P, Mohammed S, Mwangi I, Atkinson SH, **Osier F**, Peshu N, Newton CR, Maitland K, Berkley JA. Fraction of all hospital admissions and deaths attributable to malnutrition among children in rural Kenya. Am J Clin Nutr. 2008 Dec;88(6):1626-31.
  76. Beeson JG, **Osier FH**, Engwerda CR. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol. 2008 Dec;24(12):578-84.
  77. **Osier FHA**, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KKA, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon M, Conway DJ, Marsh K. "Breadth and magnitude of antibody responses to multiple *Plasmodium falciparum* merozoite antigens are associated with protection from clinical malaria." Infect Immun. 2008 May;76(5):2240-8.
  78. Verra F, Simpoire J, Warimwe GM, Tetteh KK, Howard T, **Osier FH**, Bancone G, Avellino P, Blot I, Fegan G, Bull PC, Williams TN, Conway DJ, Marsh K, Modiano D. Haemoglobin C and S Role in Acquired Immunity against *Plasmodium falciparum* Malaria. PLoS ONE. 2007 Oct 3;2(10):e978.
  79. **Osier FH**, Polley SD, Mwangi T, Lowe B, Conway DJ, Marsh K. Naturally acquired antibodies to polymorphic and conserved epitopes of *Plasmodium falciparum* merozoite surface protein 3. Parasite Immunol. 2007 Aug;29(8):387-94.
  80. **Osier FH**, Berkley JA, Newton CR. Life-threatening hyponatraemia and neurotoxicity during chemotherapy for Burkitt's lymphoma. Trop Doct. 2006 Jul;36(3):177-8.
  81. **Osier FH**, Berkley JA, Ross A, Sanderson F, Mohammed S, Newton CR. Abnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcome. Arch Dis Child. 2003 Jul;88(7):621-5.
  82. English M, Berkley J, Mwangi I, Mohammed S, Ahmed M, **Osier F**, Muturi N, Ogutu B, Marsh K, Newton CR. Hypothetical performance of syndrome-based management of acute paediatric admissions of children aged more than 60 days in a Kenyan district hospital. Bull World Health Organ. 2003;81(3):166-73.
  83. Berkley JA, Ross A, Mwangi I, **Osier FH**, Mohammed M, Shebbe M, Lowe BS, Marsh K, Newton CR. Prognostic indicators of early and late death in children admitted to district hospital in Kenya: cohort study. BMJ. 2003 Feb 15;326(7385):361.
  84. **Osier FH**, Newton CR. Fibrocalculous pancreatic diabetes in a child: case report. East Afr Med J. 1999 Dec;76(12):703-5.

### Book chapters

1. JG Beeson, FJI Fowkes, L Reiling, FH Osier, DR Drew, GV Brown "Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research" In Malaria Vaccine Development, edited by Prof Giampetro Corradin and Dr Howard Engers



